Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed sarcoma
• Soft tissue metastasis or locally recurrent disease
• Stratum I (closed to accrual as of 10/17/03):
• * Soft tissue sarcoma not specified in stratum II
• * Osteogenic sarcoma arising from soft tissue or gastrointestinal stromal tumor (GIST)
• Stratum II:
• * Ewing's sarcoma of soft tissue or bone (if measurable soft tissue metastasis is present)
• * Rhabdomyosarcoma
• * Osteogenic sarcoma of bone (if measurable soft tissue metastasis is present)
• At least 1 unidimensionally measurable lesion
• * At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• Disease progression within the past 3 months
• No prior or active known brain metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 80-100% OR
• ECOG 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• AST/ALT no greater than 2.5 times upper limit of normal
• Renal:
• Creatinine no greater than 1.5 mg/dL OR
• Creatinine clearance greater than 60 mL/min
• Cardiovascular:
• No peripheral vascular disease requiring surgical management
• No history of congestive heart failure even if it is medically controlled
• No angina pectoris even if it is medically controlled
• No myocardial infarction within the past year
• No cardiac arrhythmias
• No prior cerebrovascular event
• No prior transient ischemic attack
• No EKG evidence of acute ischemia or conduction abnormality (e.g., bifascicular block \[left anterior hemiblock in the presence of right bundle branch block\] or second or third degree atrioventricular block)
• No history of orthostatic hypotension
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior allergic reaction to compounds of similar chemical or biological composition to study drug
• No other uncontrolled concurrent illness
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No other malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
• No symptomatic peripheral neuropathy greater than grade 1
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 4 weeks since prior immunotherapy and recovered
• No concurrent biological or immunological agents
• Chemotherapy:
• Stratum I (closed to accrual as of 10/17/03):
• * At least 1 year since prior chemotherapy in the adjuvant or neoadjuvant setting
• * No other prior chemotherapy
• Stratum II:
• * No more than 1 prior chemotherapy regimen
• No concurrent chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 4 weeks since prior radiotherapy and recovered
• No concurrent radiotherapy
• Surgery:
• Not specified
• Other:
• Prior imatinib mesylate for GIST (stratum I closed to accrual as of 10/17/03) allowed
• No other concurrent investigational agents
• No concurrent commercial anticancer agents or therapies
• No concurrent combination antiretroviral therapy for HIV-positive patients